D-1073-2019 Class I Terminated
FDA drug recall D-1073-2019 was initiated by Pfizer Inc. on Mar 15, 2019 and is designated Class I. Reason for recall: Presence of Particulate Matter; glass particulates The recall status is terminated (terminated Jan 27, 2021). Affected quantity: 283,400 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 10, 2019
- Initiation Date
- Mar 15, 2019
- Termination Date
- Jan 27, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 283,400 vials
Product description
8.4% Sodium Bicarbonate Injection, USP 50 mEq (1 mEq/mL) 4.2 grams (84 mg/mL) 50 mL Single-dose fliptop vial, 25 vials per carton, Rx only Hospira, Inc. Lake Forest, IL 60045 USA ---- NDC 0409-6625-02
Reason for recall
Presence of Particulate Matter; glass particulates
Distribution pattern
United States and Puerto Rico
Code information
Lots: 79-238-EV Exp. 1 July 2019; 79-240-EV Exp. 1 July 2019; 80-088-EV Exp. 1 August 2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1073-2019
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.